Navigation Links
Cellular Dynamics Announces Commercial Launch of iCell® Endothelial Cells for Vascular-Targeted Drug Discovery
Date:9/20/2011

MADISON, Wis., Sept. 20, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced the commercial launch of human iCell® Endothelial Cells for use in vascular-targeted drug discovery, tissue regeneration and other life science research.

Endothelial cells make up the lining of blood vessels and thus are an important factor of vascular research across a multitude of disease states.  Endothelial dysfunction is a common promoter of cardiovascular disease, atherosclerosis, inflammation, thrombosis, high blood pressure and more. In addition, endothelial cells separate circulating blood from the brain, an interface known as the blood-brain barrier (BBB). While vital for protecting the brain from bacterial infections, the BBB also presents a major challenge in the delivery of diagnostic and therapeutic agents to the brain.

Unfortunately, current cell models isolated from surgical by-products, cadaveric tissue and immortalized cell lines are not truly reflective of human biology. Additional growth factors are commonly added to cultures to overcome poor growth or attachment issues at the expense of altering endothelial cell function. In addition, these cell models are limited in quantity and exhibit batch-to-batch variability.

iCell Endothelial Cells are derived from human induced pluripotent stem (iPS) cells, actively proliferate, are capable of arranging themselves into tubular formations and exhibit biochemical properties of normal human endothelial cells. Because they are human cells, they better recapitulate human biology and therefore are better predictors of drug candidate responses than current cell models.  CDI manufactures iCell Endothelial Cells in industrial quantities with more than 95% purity, which is ideal for vascular biology research, including revascularization of an organ for tissue regeneration.  

"CDI was able to provide us with the necessary endothelial cells to endothelialize our decellularized organ scaffolds.  The preliminary data look excellent," said Dr. Michael Abecassis, Founding Director of the Comprehensive Transplant Center at Northwestern University's Feinberg School of Medicine.  "We look forward to the continued use of these cells as we strive to develop tissue-engineered solutions to the severe organ shortage currently facing transplantation."

CDI has successfully engaged in pre-launch validation testing with pharmaceutical customers. The cells are useful in a variety of applications that are commonly used in vascular biology research: cell proliferation, cell invasion, and migration, cell adhesion, cell permeability, impedance/resistance and tubular formation.

"If one is interested in developing new therapeutics to treat diseases caused by human endothelial dysfunction, then the best cell model to use is human endothelial cells that recapitulate true biology," said Chris Parker, chief commercial officer of CDI.  "The problem our customers face today is that such cells have not been reproducible or available, and both academic and pharmaceutical researchers have had to make do with inferior models.  Since iCell Endothelial Cells are human and can be manufactured in high quantity, quality, and purity, we anticipate that our customers can make better decisions because their data will be based on better experimental models."

Endothelial cells are the second product CDI has now commercially launched, with neurons to follow later this year. CDI launched the first product ever developed from iPS cells, iCell Cardiomyocytes, in December 2009, just two years after human iPS cell technology was discovered in the University of Wisconsin-Madison laboratory of James Thomson, V.M.D., Ph.D. and Shinya Yamanaka (Tokyo University). Based on strong intellectual property and exclusively licensed patents from several universities, CDI has developed a proprietary process to industrialize the manufacture of virtually any cell in the human body. This capability is designed to aid drug discovery and improve the predictability of drug compound efficacy and toxicity screens early in the pharmaceutical pipeline process before significant time and resources have been invested.  

Robert Palay, chief executive officer of CDI, said, "Launching iCell Cardiomyocytes to the pharmaceutical industry in 2009 was an important step for Cellular Dynamics.  However, the launch of iCell Endothelial Cells shows we have built the infrastructure, expertise, and manufacturing pipeline to create virtually any cell type in the human body.  We look forward to launching many other iPS cell-derived iCell products."

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications.  CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools.  In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue.  CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison.  CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.


'/>"/>
SOURCE Cellular Dynamics International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
3. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
4. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
5. Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
6. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
7. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
8. Molecular Discoveries Shed Light on Liver Cancer -- Hepatocellular Carcinoma (HCC)
9. Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation
10. Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics
11. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , January 23, 2017 Longer life expectancy and ... the global market for medical device technologies. BCC Research reveals ... Asia-Pacific region, should see strong growth due to ... disposable incomes. Continue Reading ... ...
(Date:1/23/2017)... 2017  ResMed (NYSE : RMD), BMC (Pékin, Chine) et ... aujourd,hui qu,ils se sont mis d,accord sur le règlement ... BMC et 3B seront autorisés à vendre leurs produits ... et ResMed effectuera le paiement de la décision en ... de Floride entre les deux parties. Le règlement n,inclut ...
(Date:1/23/2017)... Spain , January 23, 2017 /PRNewswire/ ... biopharmaceutical company focused on treatments for calcification disorders, ... enrolled in the Phase IIb "CaLIPSO Study" clinical ... of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients ... in the last stage of chronic kidney disease, ...
Breaking Medicine Technology:
(Date:1/23/2017)... , ... January 23, 2017 , ... ... high-quality general gynecological care and gynecological services for women of all ... care for a wide variety of reproductive services from routine health screenings to ...
(Date:1/23/2017)... ... ... “Crossing the Bar”: a moving and eloquent drama depicting the events that happen ... creation of published author, Charlotte Hotte, a North Carolina native, a mother of two, ... book to her sister, Denise, wishes to acknowledge her savior, Jesus Christ, along with ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: ... from an early age. “Life Under Blankets” is the creation of published author, Kimberly ... Circle Campus in Chicago. She went on to pursue a master’s degree in education ...
(Date:1/23/2017)... ... ... Day is a time when many people celebrate romance and love by giving cards, candy, ... the ideal present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day special: ... and get $50 free. , “A lot of people just buy the more predictable ...
(Date:1/22/2017)... ... 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a unique ... buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle ... in all of its creations to help create a more traditional and natural approach ...
Breaking Medicine News(10 mins):